RealFeedApp CTAD conference discusses new Alzheimer's drug
BioGen will showcase new results for diranersen (BIIB080) at the CTAD conference. The drug uses antisense oligonucleotides to lower tau protein production in brain cells.
- Field
- ageing and longevity
- What they did
- Biogen presented new data on diranersen, a drug designed to reduce the production of tau protein in the brain.
- Why it matters
- Abnormal accumulation of tau protein damages nerve cells and leads to cognitive decline, which the drug aims to prevent.
#tau#antisense oligonucleotide#alzheimer's#biogen#clinical trial
